X0508 4 2024-02-12 false 0001560241 G1 Therapeutics, Inc. GTHX 0001706853 Malik Rajesh 700 PARK OFFICES DRIVE, SUITE 200 RESEARCH TRIANGLE PARK NC 27709 false true false false Chief Medical Officer true Common Stock 2024-02-12 4 M false 28600.00 0.30 A 198538.00 D Common Stock 2024-02-12 4 S false 28600.00 4.6204 D 169938.00 D Stock Option (Right to Buy) 0.30 2024-02-12 4 M false 28600.00 0.00 D 2025-02-27 Common Stock 28600.00 0.00 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan. The price represents the weighted average price with a low of $4.45 and a high of $4.75. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. Represents (i) 75,463 shares of common stock; (ii) 2,750 restricted stock units ("RSUs") from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iv) 13,425 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024. All shares underlying this option have vested. /s / Monica Roberts Thomas, attorney-in-fact 2024-02-13